Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says

Executive Summary

US agency's decision not to hold a February advisory committee review of tardive dyskinesia treatment viewed positively by Neurocrine, which emphasized quality of its communications with the review division and the drug's breakthrough therapy status.

Advertisement

Related Content

Neurocrine's US Label For Ingrezza Should Provide Edge Over Teva's Austedo In TD
US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?
US FDA Review Management Challenged After Spate Of Complete Response Letters
Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says
Neurocrine Gets First Drug For Tardive Dyskinesia To FDA
Teva Remains Focused On Tardive Dyskinesia After Huntington’s Stumble
CNS Therapies Contribute Rising Share Of Breakthrough Designations
Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene
Repros At A Loss After FDA Abruptly Cancels Enclomiphene Panel Review
Purdue's Pain And No Gain: More Analysis Of OxyContin Postmarket Studies Needed

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel